Navigation Links
Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
Date:5/9/2008

KENILWORTH, N.J., May 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) will hold its Annual Meeting of Shareholders Friday, May 16, 2008, in Memphis, Tenn. At 8 a.m. (CDT) (9 a.m. EDT) on that day, a live Webcast of the meeting will be available to all interested parties via the corporate Web site, http://www.schering-plough.com.

At the Annual Meeting, Fred Hassan, Chairman and CEO, will report to shareholders on the company's performance and the progress being achieved toward its long-term goals.

Those wishing to listen live to the Webcast of the Annual Meeting should go to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and click on the "Presentations/Webcasts" link. A replay of the Webcast will be available via the Web site later that day.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
2. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
3. Schering-Plough CEO Buys $2 Million in Common Shares
4. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
5. Schering-Plough Reports Financial Results for First Quarter of 2008
6. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
7. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
8. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
9. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
10. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
11. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... for cancer, today announced the appointment of Thomas C Reynolds ... over 20 years, development experience gained in the biotechnology industry, ... "I am delighted to welcome Tom at this transformative ...
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... Oct. 21 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... nationwide and internationally, is pleased to announce that Chairman, CEO ... Operations, will appear for one hour live on "Go Rogue ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... financial results on Wednesday, October 27, 2010, after the market ... call at 5:00 p.m. ET, which will be open to ... the company will review the financial results and discuss other ...
... and NEW YORK, Oct. 20 ACCESS ... ACCP ), a biopharmaceutical company leveraging its proprietary drug-delivery ... supportive care and diabetes, announced it has submitted additional ... formulations of many global top-100 injectable drugs, as a ...
Cached Biology Technology:Cord Blood America Management Team to Appear on National VoiceAmerica Radio Network 2Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3
(Date:7/9/2014)... of Adlie penguins shows that the population is ... than previously estimated. Adlie penguins have long been ... understand the effects of climate change and fishing ... satellite imagery, researchers from Stony Brook University and ... that permits regular monitoring of Adlie penguins across ...
(Date:7/9/2014)... an economy driven by methane, the primary component of natural ... production boom. It has poised the country as a top ... over just how climate-friendly it is, according to an article ... news magazine of the American Chemical Society. , In the ... when burned as a fuel to produce electricity, methane emits ...
(Date:7/9/2014)... at the NIH,s National Center for Advancing ... treat sickle cell disease has been acquired ... candidate, Aes-103, is the first specifically developed ... sickle cell disease. Baxter now will advance ... approval and commercialization. , Sickle cell disease ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... 5, 2008 Scientists report online this week in ... of specialized gut immune cells to a gene associated ... inflammatory bowel disorder. The link to immune cells ... St. Louis because they and others believe Crohn,s disease ...
... found the key to engineering plants capable of thriving ... report published online on October 2nd in Current ... that is generally plentiful in the earth,s crustcauses particular ... where acidic environments turn the metal into a form ...
... the power of 21st century computing to confirm an idea ... cycles evolve faster. Their findings appear in the October 3rd ... consequence for the understanding of evolution made possible by the ... said senior author Michael Donoghue , the G. Evelyn ...
Cached Biology News:Form of Crohn's disease traced to disabled gut cells 2How to build crops that can beat aluminum's toxic effects 2Reproducing early and often is the key to rapid evolution in plants 2
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
X-gal,1g...
...
Biology Products: